Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1221-1227

  Mamat, Suhana ^a,b   Ikeda, Jun Ichiro ^a   Enomoto, Takayuki ^a   Ueda, Yutaka ^a   Rahadiani, Nur ^a   Tian, Tian ^a   Wang, Yi ^a   Qiu, Ying ^a   Kimura, Tadashi ^a   Aozasa, Katsuyuki ^a   Morii, Eiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

CDCP1; Endometrioid adenocarcinoma; Immunohistochemistry; Normal endometrium; Prognosis

Indexed keywords

CDCP 1 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID ADENOCARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECURRENCE RISK; STAINING; TUMOR CELL;

ADULT; AGED; ANTIGENS, CD; CARCINOMA, ENDOMETRIOID; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950820633     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000753     Document Type: Article

References (17)

1. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P and Shweifer N: Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20: 4402-4408, 2001. (Pubitemid 32726882)
2. Hooper JD, Zijlstra A, Aimes RT, et al: Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22: 1783-1794, 2003. (Pubitemid 36513138)
3. Brown TA, Yang TM, Zaitsevskaia T, Xia Y, Dunn CA, Sigle RO, Knudsen B and Carter WG: Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. J Biol Chem 279: 14772-14783, 2004. (Pubitemid 38618866)
4. Benes CH, Wu N, Elia AEH, Dharia T, Cantley LC and Soltoff SP: The C2 domain of PKC-delta is a phosphotyrosine binding domain. Cell 121: 271-280, 2005.
5. Conze T, Lammers R, Kuci S, Scherl-Mostageer M, Schweifer N, Kanz L and Buhring HJ: CDCP1 is a novel marker for hematopoietic stem cells. Ann NY Acad Sci 996: 222-226, 2003. (Pubitemid 36706603)
6. Buhring HJ, Kuci S, Conze T, et al: CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and non-hematopoietic origin. Stem Cells 22:334-343, 2004. (Pubitemid 38736617)
7. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T and Sakai R: CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 27: 7649-7660, 2007. (Pubitemid 350033670)
8. Ikeda JI, Morii E, Kimura H, et al: Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 210: 75-84, 2006. (Pubitemid 44288183)
9. Kimura H, Morii E, Ikeda JI, et al: Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells. Leukemia 20: 1551-1556, 2006. (Pubitemid 44264098)
10. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, Aozasa K and Morii E: Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 100: 429-433, 2009.
11. Awakura Y, Nakamura E, Takahashi T, et al: Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 134: 1363-1369, 2008.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
13. Horn LC, Meinel A, Handzel R and Einenkel J: Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol 1: 297-311, 2007. (Pubitemid 47043499)
14. Zaino RJ: FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28: 1-9, 2009.
15. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998. (Pubitemid 28144151)
16. Steiner E, Eicher O, Sagemuller J, et al: Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 13: 197-203, 2003.
17. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H and Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 13: 379-388, 2000.